Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -1.36 | -0.76 | -4.01 |
| FCF Yield | 1.87% | 1.08% | 2.31% | 1.65% |
| EV / EBITDA | 30.17 | 56.14 | 48.77 | 46.52 |
| Quality | ||||
| ROIC | 3.54% | 1.33% | 1.74% | 2.40% |
| Gross Margin | -16.26% | 76.91% | 75.42% | 78.48% |
| Cash Conversion Ratio | -0.64 | 1.82 | 2.09 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.58% | 10.30% | 11.16% | 11.47% |
| Free Cash Flow Growth | -81.10% | -55.04% | 31.57% | 277.32% |
| Safety | ||||
| Net Debt / EBITDA | 3.43 | 6.19 | 5.67 | 6.01 |
| Interest Coverage | 16.86 | 4.68 | 5.18 | 7.39 |
| Efficiency | ||||
| Inventory Turnover | 1.95 | 0.33 | 0.41 | 0.38 |
| Cash Conversion Cycle | 136.84 | 307.60 | 254.58 | 276.00 |